Expression of MUC1, MUC2, MUC5AC, and MUC6 in atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar carcinoma of the lung.
暂无分享,去创建一个
[1] H. Popper,et al. Atypical Adenomatous Hyperplasia of the Lung: A Probable Forerunner in the Development of Adenocarcinoma of the Lung , 2001, Modern Pathology.
[2] S Sone,et al. High-resolution CT analysis of small peripheral lung adenocarcinomas revealed on screening helical CT. , 2001, AJR. American journal of roentgenology.
[3] A. Sonnenberg,et al. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components , 1995, The Journal of cell biology.
[4] A. Hölscher,et al. Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl‐Lewisa and sialyl‐Lewisx antigens in colorectal adenocarcinoma , 2002, Histopathology.
[5] N. Kohno,et al. Decreased MUC1 expression induces E-cadherin-mediated cell adhesion of breast cancer cell lines. , 1998, Cancer research.
[6] R. Hruban,et al. p53 alterations in atypical alveolar hyperplasia of the human lung. , 1998, Human pathology.
[7] Y. Nakanuma,et al. Expression of MUC2, MUC5AC and MUC6 apomucins in carcinoma, dysplasia and non‐dysplastic epithelia of the gallbladder , 1999, Pathology international.
[8] I. van Seuningen,et al. Transcriptional regulation of the 11p15 mucin genes. Towards new biological tools in human therapy, in inflammatory diseases and cancer? , 2001, Frontiers in bioscience : a journal and virtual library.
[9] S. Chae,et al. Coexpression of MUC1 with p53 or MUC2 correlates with lymph node metastasis in colorectal carcinomas. , 2002, Journal of Korean medical science.
[10] Y. Shimosato,et al. Histological Typing of Lung and Pleural Tumours , 1999, World Health Organization.
[11] Takaaki Ito,et al. Reduced expression of p27/Kip1 is associated with the development of pulmonary adenocarcinoma , 2000, The Journal of pathology.
[12] Y. Takeshima,et al. Correlation between genetic alterations and histopathological subtypes in bronchiolo‐alveolar carcinoma and atypical adenomatous hyperplasia of the lung , 2000, Pathology international.
[13] A. Harris,et al. MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. , 1998, Journal of clinical pathology.
[14] J. Jass,et al. Significance of MUC1 and MUC2 mucin expression in colorectal cancer. , 1996, Journal of clinical pathology.
[15] H. Stein,et al. MUC2 gene suppression in human colorectal carcinomas and their metastases: in vitro evidence of the modulatory role of DNA methylation. , 1997, Laboratory investigation; a journal of technical methods and pathology.
[16] M. Copin,et al. Induction of MUC2 and MUC5AC Mucins by Factors of the Epidermal Growth Factor (EGF) Family Is Mediated by EGF Receptor/Ras/Raf/Extracellular Signal-regulated Kinase Cascade and Sp1* , 2002, The Journal of Biological Chemistry.
[17] K. Eguchi,et al. Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[18] C. Melief,et al. Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. , 1993, Journal of immunology.
[19] Y. Nishiwaki,et al. Monoclonality of atypical adenomatous hyperplasia of the lung. , 1999, The American journal of pathology.
[20] D Hoffmann,et al. Smoking and lung cancer: scientific challenges and opportunities. , 1994, Cancer research.
[21] K. Imai,et al. Effect of MUC1 Mucin, an Anti‐adhesion Molecule, on Tumor Cell Growth , 1996, Japanese journal of cancer research : Gann.
[22] M. Pasdar,et al. The importance of MUC1 cellular localization in patients with breast carcinoma , 2001, Cancer.
[23] S. Daya. Fisher exact test , 2002 .
[24] R. Hruban,et al. K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. , 1996, Cancer research.
[25] S. Steinberg,et al. MUC1 is a novel marker for the type II pneumocyte lineage during lung carcinogenesis. , 1998, Cancer research.
[26] A. Marchetti,et al. BRONCHIOLOALVEOLAR LUNG CARCINOMAS: K‐ras MUTATIONS ARE CONSTANT EVENTS IN THE MUCINOUS SUBTYPE , 1996, The Journal of pathology.
[27] S. Crawley,et al. Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas. , 2002, Gastroenterology.
[28] S. Tsuchida,et al. Transcriptional Activation of the MUC2 Gene by p53* , 2002, The Journal of Biological Chemistry.
[29] K. Sugimachi,et al. Lung adenocarcinoma with bronchioloalveolar carcinoma component is frequently associated with foci of high-grade atypical adenomatous hyperplasia. , 2002, American journal of clinical pathology.
[30] S. Barsky,et al. Rising incidence of bronchioloalveolar lung carcinoma and its unique clinicopathologic features , 1994, Cancer.
[31] G. Pruneri,et al. Depolarized expression of episialin (EMA, MUC1) in lung adenocarcinoma is associated with tumor progression. , 1998, Anticancer research.
[32] J. Lloreta,et al. Mucins as differentiation markers in bronchial epithelium. Squamous cell carcinoma and adenocarcinoma display similar expression patterns. , 2001, American journal of respiratory cell and molecular biology.
[33] C. A. Carraway,et al. Muc4/sialomucin complex, the intramembrane ErbB2 ligand, induces specific phosphorylation of ErbB2 and enhances expression of p27kip, but does not activate mitogen-activated kinase or protein kinaseB/Akt pathways , 2002, Oncogene.